ES2487271T3 - Formulaciones de dosificación sólidas inhibidoras de DPP-IV - Google Patents

Formulaciones de dosificación sólidas inhibidoras de DPP-IV Download PDF

Info

Publication number
ES2487271T3
ES2487271T3 ES12187333.5T ES12187333T ES2487271T3 ES 2487271 T3 ES2487271 T3 ES 2487271T3 ES 12187333 T ES12187333 T ES 12187333T ES 2487271 T3 ES2487271 T3 ES 2487271T3
Authority
ES
Spain
Prior art keywords
dpp
solid dosage
dosage formulations
inhibitor solid
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12187333.5T
Other languages
English (en)
Inventor
Ümit Cifter
Ali TÜRKYILMAZ
Mehtap Saydam
Gülay Yelken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Application granted granted Critical
Publication of ES2487271T3 publication Critical patent/ES2487271T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación de dosificación farmacéutica sólida obtenida con prensado en briquetas o compresión entre rodillos y caracterizada por que comprende un inhibidor de DPP-IV con al menos un excipiente aglutinante de granulación en seco que es policarbófilo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES12187333.5T 2011-10-06 2012-10-05 Formulaciones de dosificación sólidas inhibidoras de DPP-IV Active ES2487271T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201109893 2011-10-06
TR201109893 2011-10-06

Publications (1)

Publication Number Publication Date
ES2487271T3 true ES2487271T3 (es) 2014-08-20

Family

ID=46940413

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12187333.5T Active ES2487271T3 (es) 2011-10-06 2012-10-05 Formulaciones de dosificación sólidas inhibidoras de DPP-IV

Country Status (3)

Country Link
EP (1) EP2578208B1 (es)
ES (1) ES2487271T3 (es)
PL (1) PL2578208T3 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105520913A (zh) * 2014-09-28 2016-04-27 石药集团中奇制药技术（石家庄）有限公司 一种包含沙格列汀的微丸、其用途及其制备方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014030051A1 (en) * 2012-08-23 2014-02-27 Aurobindo Pharma Limited Stable pharmaceutical compositions comprising saxagliptin
WO2015071887A1 (en) * 2013-11-18 2015-05-21 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of saxagliptin
WO2015114152A1 (en) * 2014-02-03 2015-08-06 Galenicum Health S.L. Stable pharmaceutical compositions containing sitagliptin in the form of immediate release tablets
US20170014380A1 (en) * 2014-03-06 2017-01-19 Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi Vildagliptin Formulation Process Under Inert Gas Atmosphere
TR201402685A1 (tr) * 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.
AU2015295846B2 (en) * 2014-07-30 2020-07-09 Merck Patent Gmbh Directly compressible composition containing micro-crystalline cellulose
MA40868A (fr) * 2014-10-30 2017-09-05 Sanovel Ilac Sanayi Ve Ticaret As Combinaisons pharmaceutiques de sitagliptine et d'agonistes de ppar
CN105168177B (zh) * 2015-09-24 2020-05-05 江苏威凯尔医药科技有限公司 沙格列汀胶囊及其制备方法
WO2017115252A1 (en) 2015-12-28 2017-07-06 Wockhardt Limited An oral osmotic pharmaceutical composition of vildagliptin
CN110051685A (zh) * 2019-03-13 2019-07-26 安庆瑄宇医药科技有限公司 一种维达列汀降糖咀嚼片及其制备方法
JP7299984B2 (ja) * 2019-08-01 2023-06-28 沢井製薬株式会社 ビルダグリプチン含有乾式造粒末、ビルダグリプチン含有錠剤及びその製造方法
EP4045048A4 (en) 2019-10-14 2023-05-24 Santa Farma Ilaç Sanayi A.S. ORAL FORMULATIONS COMPRISING SITAGLIPTIN HCI MONOHYDRATE WITH ENHANCED PHARMACEUTICAL CHARACTERISTICS
CN112250505A (zh) * 2020-10-30 2021-01-22 云南云天化红磷化工有限公司 一种速溶粒状磷铵用崩解剂及其制备方法和应用
CN116139092A (zh) * 2023-04-17 2023-05-23 山东新时代药业有限公司 一种维格列汀片剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
US7214702B2 (en) 2004-05-25 2007-05-08 Bristol-Myers Squibb Company Process for producing a dipeptidyl peptidase IV inhibitor
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
GT200600008A (es) 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
WO2007096906A2 (en) * 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
KR20120006047A (ko) 2009-04-09 2012-01-17 산도즈 아게 삭사글립틴의 결정 형태

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105520913A (zh) * 2014-09-28 2016-04-27 石药集团中奇制药技术（石家庄）有限公司 一种包含沙格列汀的微丸、其用途及其制备方法
CN105520913B (zh) * 2014-09-28 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 一种包含沙格列汀的微丸、其用途及其制备方法

Also Published As

Publication number Publication date
PL2578208T3 (pl) 2014-10-31
EP2578208B1 (en) 2014-05-21
EP2578208A1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
ES2487271T3 (es) Formulaciones de dosificación sólidas inhibidoras de DPP-IV
ES2471951T3 (es) Procedimiento y dispositivo para el estampado en caliente
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
ES2509117T3 (es) Composición farmacéutica oral que contiene dabigatran etexilato
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
ES2496892T3 (es) Formulaciones para el tratamiento de trastornos del tracto respiratorio superior
ES2527242T3 (es) Composiciones que comprenden un germinante y un agente antimicrobiano
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
AR057181A1 (es) Nueva forma de dosificacion de combinacion
ES2486615A2 (es) Formulación, resina o extruido para conformar una estructura celular aislante, polimérica y no aromática, artículo y material que se obtiene, recipiente conformado y proceso de obtención.
CL2009000882A1 (es) Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer.
ES2525918T3 (es) Proceso para la fabricación de Nicorandil
ES2640291T3 (es) Sistema de iluminación fotográfica para tableta táctil
CL2014001337A1 (es) Formulacion farmaceutica oral solida que comprende una dispersion solida que comprende a su vez un compuesto especifico derivado de 4-(1-isopropil-1h-pirazol-4-il)-pirimidina y su uso en el tratamiento de una enfermedad proliferativa.
ES2508165T3 (es) Lactoferrina y sustancia blanca
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
CL2016001350A1 (es) Composiciones de ketoprofeno de accion prologanda.
CL2016000788A1 (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016)
DOP2015000042A (es) Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa
ES2525668T3 (es) Composición farmacéutica que comprende tramadol y quetoprofeno en asociación
ES2510403T3 (es) Composición antioxidante, sinérgica